1. Strizzi L, Postovit LM, Margaryan NV, et al. Emerging
roles of nodal and Cripto-1: from embryogenesis to
breast cancer progression. Breast Dis 2008; 29: 91-
103.
2. Leong KG, Gao WQ. The Notch pathway in prostate
development and cancer. Differentiation 2008; 76:
699-716.
3. Raaijmakers MH, Scadden DT. Divided within: heterogeneity
within adult stem cell pools. Cell 2008;
135: 1006-1008.
4. Dick JE. Stem cell concepts renew cancer research.
Blood 2008; 112: 4793-4807.
5. Pearce DJ, Ridler CM, Simpson C, Bonnet D.
Multiparameter analysis of murine bone marrow side
population cells. Blood 2004; 103: 2541-2546.
26
Öktem G ve ark.
27
6. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct
"side population" of cells in human tumor cells:
implications for tumor biology and therapy. Cell Cycle
2005; 4: 203-205.
7. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct
"side population" of cells with high drug efflux
capacity in human tumor cells. Proc Natl Acad Sci
USA 2004; 101: 14228-14233.
8. Patrawala L, Calhoun T, Schneider-Broussard R, et al.
Side population is enriched in tumorigenic, stem-like
cancer cells, whereas ABCG2+ and ABCG2- cancer
cells are similarly tumorigenic. Cancer Res 2005; 65:
6207-6219.
9. Chen J, Crabbe A, Duppen VV, Vankelecom H The
notch signaling system is present in the postnatal pituitary:
marked expression and regulatory activity in the
newly discovered side population. Mol Endocrinol
2006; 20: 3293-3307.
10. Bozkurt KM. Kemoterapi ve Kanser Kök Hücreleri.
‹stanbul: Uyum Yay›nc›l›k; 2007.
11. Marotta LL, Polyak K. Cancer stem cells: a model in
the making. Curr Opin Genet Dev 2009; 19: 44-50.
12. Morrow M, Wait RB, Rosenthal RA, Gamelli RL.
Verapamil enhances antitunor activity without
increasing myeloid toxicity. Surgery 1987; 101: 63-68.
13. fienel F. Klonlamada yeni ufuklar: Kök hücreler.
TÜB‹TAK Bilim ve Teknik Dergisi 2002; (410): 44.
14. Cheng XY, O’Neill HC. Oncogenesis and cancer stem
cells: Current opinions and future directions. J Cell
Mol Med 2009; 16.
15. Ward RJ, Dirks PB. Cancer stem cells: at the headwaters
of tumor development. Annu Rev Pathol 2007; 2:
175-189.
16. Szakács G, Jakab K, Antal F, Sarkadi B. Diagnostics of
multidrug resistance in cancer. Pathol Oncol Res
1998; 4: 251-257.
17. Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP,
Shoemaker R, Mertelsmann R. Induction of multipledrug
resistance during anti- neoplastic chemotherapy
in vitro. Int J Cancer 1991; 49: 630-637
18. BJ, Osborne BA, Miele L. Notch signaling as a therapeutic
target in cancer: a new approach to the development
of cell fate modifying agents. Oncogene 2003;
22: 6598-6608.
19. Singh SR, Hou SX. Multipotent stem cells in the
Malpighian tubules of adult Drosophila melanogaster.
J Exp Biol 2009; 212: 413-23.
20. Koch U, Radtke F. Notch and cancer: a double- edged
sword. Cell Mol Life Sci 2007; 64: 2746-2762.
21. Bolós V, Blanco M, Medina V, Aparicio G, Díaz-Prado
S, Grande E. Notch signalling in cancer stem cells.
Clin Transl Oncol 2009; 11: 11-9.
22. Akbulut H, Akbulut KG. Karsinogenez In: Içli F, ed.
T›bbi Onkoloji. Ankara: ANTIP Afi T›p Kitaplar› ve
Bilimsel Yay›nlar; 1997. p. 23-38.
23. Lecture GFF. Molecular mechanisms of lung cancer.
Interaction of environmental and genetic factors. Chest
1996; 109: 14-19.
